Alliance Global Partners Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $8.5
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners has initiated coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and set a price target of $8.5. The announcement was made by analyst Scott Henry.

February 16, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alliance Global Partners initiated coverage on Journey Medical with a Buy rating and a price target of $8.5.
The initiation of coverage by a reputable firm like Alliance Global Partners with a Buy rating and a specific price target usually generates positive sentiment among investors. This can lead to increased investor interest and potentially drive the stock price up in the short term, especially if the market perceives the analysis as well-founded and agrees with the valuation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100